Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05306080 · ClinicalTrials.gov registry record · Early Phase 1
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
A Early Phase 1 study of HLH and CRS - Cytokine Release Syndrome, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05306080 is a Early Phase 1 study of HLH and CRS - Cytokine Release Syndrome that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05306080, a Early Phase 1 study of HLH and CRS - Cytokine Release Syndrome, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).
Conditions Studied
Interventions
- DRUG Tadekinig alfa (IL-18BP)
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-04-17 |
| Est. Completion | 2028-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05306080
The ClinicalTrials.gov registry entry for NCT05306080 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HLH appearing as the primary indexed condition, and to 1 intervention - of which Tadekinig alfa (IL-18BP) is the first listed.
NCT05306080 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05306080 about?
NCT05306080 is a clinical study titled "Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome". This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).
What is the current status of trial NCT05306080?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2022-04-17. Estimated completion is 2028-04.
What conditions does trial NCT05306080 study?
This clinical trial studies the following conditions: HLH, CRS - Cytokine Release Syndrome.
What interventions are being tested in trial NCT05306080?
The interventions under investigation include: Tadekinig alfa (IL-18BP) (DRUG).
Who is sponsoring clinical trial NCT05306080?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05306080 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HLH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.